MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT The…
Categorie
Blood Cancers
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease The…
January 8, 2025
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
January 7, 2025
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting MaaT Pharma…
December 10, 2024
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute…
December 5, 2024
MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd 2024 –7.30 am CET –…
April 22, 2024
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access…
April 15, 2024
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.